Yi-Bin Xiao1, Bo Zhang1, Yu-Lian Wu1. 1. Department of Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
Abstract
OBJECTIVE: To evaluate the comparative therapeutic efficacy of radiofrequency ablation (RFA) and hepatic resection (HR) for breast cancer liver metastases (BCLMs). METHODS: Studies that had examined the outcomes for both RFA and HR for BCLM were identified by searching the electronic databases PubMed, EMBASE, and the Cochrane Library. Pooled analyzes of the overall survival (OS), disease-free survival (DFS), and short-term outcomes of BCLM were performed. RESULTS: Patients with BCLM gained many more survival benefits from HR than from RFA with regard to the 3-year OS rate (combined odds ratio (OR) 0.41, 95% confidence interval (CI) 0.29-0.59, P<0.001), 5-year OS rate (combined OR 0.38, 95% CI 0.32-0.46, P<0.001), 3-year DFS (combined OR 0.36, 95% CI 0.27-0.49, P<0.001), and 5-year DFS (combined OR 0.51, 95% CI 0.40-0.66, P<0.001). RFA had fewer postoperative complications (combined OR 0.30, 95% CI 0.20-0.44, P<0.001) and shorter hospital stays (combined OR -9.01, 95% CI -13.49-4.54, P<0.001) than HR. CONCLUSIONS: HR takes precedence over RFA in the treatment of patients with BCLM, considering the better survival rate. RFA gives rise to fewer complications and can be carried out with a shorter hospital stay, compared to HR. RFA should be reserved for patients who are not optimum candidates for resection.
OBJECTIVE: To evaluate the comparative therapeutic efficacy of radiofrequency ablation (RFA) and hepatic resection (HR) for breast cancer liver metastases (BCLMs). METHODS: Studies that had examined the outcomes for both RFA and HR for BCLM were identified by searching the electronic databases PubMed, EMBASE, and the Cochrane Library. Pooled analyzes of the overall survival (OS), disease-free survival (DFS), and short-term outcomes of BCLM were performed. RESULTS: Patients with BCLM gained many more survival benefits from HR than from RFA with regard to the 3-year OS rate (combined odds ratio (OR) 0.41, 95% confidence interval (CI) 0.29-0.59, P<0.001), 5-year OS rate (combined OR 0.38, 95% CI 0.32-0.46, P<0.001), 3-year DFS (combined OR 0.36, 95% CI 0.27-0.49, P<0.001), and 5-year DFS (combined OR 0.51, 95% CI 0.40-0.66, P<0.001). RFA had fewer postoperative complications (combined OR 0.30, 95% CI 0.20-0.44, P<0.001) and shorter hospital stays (combined OR -9.01, 95% CI -13.49-4.54, P<0.001) than HR. CONCLUSIONS: HR takes precedence over RFA in the treatment of patients with BCLM, considering the better survival rate. RFA gives rise to fewer complications and can be carried out with a shorter hospital stay, compared to HR. RFA should be reserved for patients who are not optimum candidates for resection.
Entities:
Keywords:
Breast cancer liver metastasis; Radiofrequency ablation; Hepatic resection; Prognosis; Meta-analysis
Authors: Icro Meattini; Isacco Desideri; Giulio Francolini; Agnese Vannini; Marco Perna; Pietro Garlatti; Roberta Grassi; Lorenzo Livi Journal: Med Oncol Date: 2017-03-31 Impact factor: 3.064
Authors: S P Corona; N Sobhani; A Ianza; G Roviello; G Mustacchi; M Bortul; F Zanconati; D Generali Journal: Med Oncol Date: 2017-05-19 Impact factor: 3.064
Authors: Sebastian Keil; Philipp Bruners; Lutz Ohnsorge; Cedric Plumhans; Florian F Behrendt; Sven Stanzel; Michael Sühling; Rolf W Günther; Marco Das; Andreas H Mahnken Journal: J Vasc Interv Radiol Date: 2010-02 Impact factor: 3.464
Authors: C T Sofocleous; R G Nascimento; M Gonen; M Theodoulou; A M Covey; L A Brody; S M Solomon; R Thornton; Y Fong; G I Getrajdman; K T Brown Journal: AJR Am J Roentgenol Date: 2007-10 Impact factor: 3.959
Authors: Dawid Storman; Mateusz J Swierz; Robert P Riemsma; Robert Wolff; Jerzy W Mitus; Michal Pedziwiatr; Jos Kleijnen; Malgorzata M Bala Journal: Cochrane Database Syst Rev Date: 2021-01-28